| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7655019 | Revue Francophone des Laboratoires | 2012 | 8 Pages |
Abstract
Lung cancer is the leading cause of cancer-related deaths in the world. Non-small cell lung cancer (NSCLC) represents a heterogeneous group mainly consisting of adenocarcinoma, whose incidence is rising. The management of NSCLC is now moving from standard chemotherapy to more targeted therapies according to histological and molecular markers. Indeed the TNM classification has been modified in 2009 and the WHO classification should change according to IASLC/ATS/ERS classification, particularly for adenocarcinoma. The development of targeted therapies in the treatment of lung carcinoma has also completely changed the management of tumoral samples regarding the histological subtype diagnostic assessment and the molecular characteristics.
Related Topics
Physical Sciences and Engineering
Chemistry
Analytical Chemistry
Authors
Audrey Mansuet-Lupo, Thierry Jo Molina, Diane Damotte,